Why Is PODD Stock Dropping Today? Insulet Falls 18% After Cutting Guidance

Insulet Corporation (PODD) shares fell 18. 18.02% in intraday trading on Wednesday after the diabetes technology company cut its full-year sales growth forecast and issued third-quarter guidance that fell short of analyst expectations.

What Did Insulet Report?

The company reported second-quarter adjusted earnings of $1.66 per share on revenue of $801.7 million, topping consensus estimates on both the top and bottom lines. The beat was overshadowed by the outlook, however. Management lowered its 2026 full-year revenue growth guidance to 20% to 22%, down from a prior range of 21% to 23%, and cut its U.S. Omnipod growth outlook to 17% to 19% from 20% to 22%. For the third quarter, Insulet guided for revenue of roughly $833.4 million, missing the $847.3 million that analysts had projected, and pointed to softer expected sales in the second half of the year.

Why Did Investors React?

The sell-off reflects a market that is weighing the forward-looking growth trajectory more heavily than the backward-looking quarterly beat. The U.S. Omnipod franchise — Insulet's flagship product line — is the focal point of the concern. A 3-percentage-point reduction in the growth outlook for the core business signals a meaningful deceleration, and investors who have valued the stock for its consistent high-growth profile are recalibrating.

The Q3 revenue guidance miss adds weight to the bearish read: it suggests the softness is not a one-quarter stumble but a trend that management expects to continue through year-end. For a stock that has historically commanded a premium valuation on the back of its growth trajectory, even a modest deceleration can trigger an outsized repricing.

What Comes Next?

Trading volume was significantly elevated, with relative volume running at roughly 3.7 times the 20-day average, pointing to broad-based institutional repositioning in the stock.

The primary risk is that the guidance cut marks the start of a broader reset of growth expectations. If the Omnipod franchise's trajectory continues to moderate beyond the revised range, the stock's valuation could face additional pressure, and short-term volatility may remain elevated as analysts digest the new outlook.

The third-quarter earnings report will be the next major checkpoint, showing whether the guidance cut proved conservative or whether the softer second-half dynamic plays out as management now expects. In the near term, analyst revisions to revenue and earnings estimates will be a key signal of how the Street is recalibrating expectations for the Omnipod franchise.